Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Executive Summary
Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)